All In Biotech

Investigational drug · Phase 3

ASP2138

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma.

Phase 3

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 3

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3

Any phase or sponsor naming "ASP2138"

First trial start

2026

Jul 28, 2026

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "ASP2138", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Gastric Adenocarcinoma
  • Gastroesophageal Junction (GEJ) Adenocarcinoma

Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver

Largest trials

Live from ClinicalTrials.gov: studies naming "ASP2138" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 0 on PubMed

No PubMed records name it yet, which is common for early code-named drugs.

Also in development for Gastric Adenocarcinoma

  • QLS31905Phase 35 trials

    Qilu Pharmaceutical Co., Ltd. · Advanced Solid Tumor, CLDN18.2-positive Advanced Biliary Tract Cancer, Gastric Adenocarcinoma

  • ASKB589Phase 33 trials

    AskGene Pharma, Inc. · Gastric Cancer, Gastroesophageal Cancer (GC), Malignant Solid Tumor

  • DenikitugGS-1811, DENPhase 22 trials

    Gilead Sciences · Advanced Microsatellite Stable Colorectal Cancer, HER2-negative, Gastroesophageal Junction

  • TRK-950Phase 22 trials

    Toray Industries, Inc · Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma

  • BHB810Phase 21 trial

    BigHat Biosciences, Inc. · Gastric Cancer, Gastric Adenocarcinoma, Gastric (Stomach) Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Astellas.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.